Stockreport

Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

Krystal Biotech, Inc.  (KRYS) 
Last krystal biotech, inc. earnings: 11/4 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.krystalbio.com/investors
PDF Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with suc [Read more]